PURPOSE OF REVIEW: Frailty is common in chronic kidney disease (CKD) and is a predictor of adverse outcomes. The current article reviews the most common frailty measures available, gives an overview of their use in the chronic kidney disease population, and summarizes their strengths and limitations. RECENT FINDINGS: Frailty is increasingly recognized as a potent predictor of adverse outcomes in all stages of chronic kidney disease. Recent investigations have demonstrated that the clinical perception of frailty by healthcare personnel or patients themselves is an inaccurate measure of frailty. The clinical frailty scale, a simple point-of-care tool for the assessment of frailty, has been shown to be a predictor of mortality in individuals on dialysis. SUMMARY: The Fried criteria have been most extensively used in chronic kidney disease. However, other criteria using self-reported outcomes, clinical and cognitive criteria have also been shown to predict adverse outcomes and may be more applicable in clinical settings. Many of these still require further validation in the chronic kidney disease population.
PURPOSE OF REVIEW: Frailty is common in chronic kidney disease (CKD) and is a predictor of adverse outcomes. The current article reviews the most common frailty measures available, gives an overview of their use in the chronic kidney disease population, and summarizes their strengths and limitations. RECENT FINDINGS: Frailty is increasingly recognized as a potent predictor of adverse outcomes in all stages of chronic kidney disease. Recent investigations have demonstrated that the clinical perception of frailty by healthcare personnel or patients themselves is an inaccurate measure of frailty. The clinical frailty scale, a simple point-of-care tool for the assessment of frailty, has been shown to be a predictor of mortality in individuals on dialysis. SUMMARY: The Fried criteria have been most extensively used in chronic kidney disease. However, other criteria using self-reported outcomes, clinical and cognitive criteria have also been shown to predict adverse outcomes and may be more applicable in clinical settings. Many of these still require further validation in the chronic kidney disease population.
Authors: Ismay N van Loon; Namiko A Goto; Franciscus T J Boereboom; Michiel L Bots; Marianne C Verhaar; Marije E Hamaker Journal: Clin J Am Soc Nephrol Date: 2017-07-17 Impact factor: 8.237
Authors: Shoshana H Ballew; Yan Chen; Natalie R Daya; Job G Godino; B Gwen Windham; Mara McAdams-DeMarco; Josef Coresh; Elizabeth Selvin; Morgan E Grams Journal: Am J Kidney Dis Date: 2016-11-22 Impact factor: 8.860
Authors: Clara J Bohm; Leroy J Storsley; Brett M Hiebert; Serena Nelko; Navdeep Tangri; Lawrence J Cheskin; Mara A McAdams-DeMarco; Claudio Rigatto Journal: Can J Kidney Health Dis Date: 2018-02-19